Gabriel Kacsó

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

Karim Fizazi, Stéphanie Foulon, Joan Carles et al. · The Lancet · 2022 · 716 citations · Full text

Factorial Design, Urology, × 2 +9

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

Sylvie Bonvalot, Piotr Rutkowski, Juliette Thariat et al. · The Lancet Oncology · 2019 · 469 citations · Full text

Radiation Medicine, Radiation Therapy, Medicine +10

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m²) and the Currently Approved Dose (25 mg/m²) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer—PROSELICA

Mario A. Eisenberger, Anne-Claire Hardy-Bessard, Choung‐Soo Kim et al. · Journal of Clinical Oncology · 2017 · 282 citations

Gold nanoparticles conjugated with cisplatin/doxorubicin/capecitabine lower the chemoresistance of hepatocellular carcinoma-derived cancer cells.

Ciprian Tomuleasa, Olga Şoriţău, Anamaria Orza et al. · PubMed · 2012 · 102 citations

Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma.

Ciprian Tomuleasa, Olga Şoriţău, Dan Rus-Ciucă et al. · PubMed · 2010 · 88 citations